HH&L Acquisition Co. Announces Closing of Upsized $414 Million Initial Public Offering and Exercise of Underwriters' Over-Allotment Option in Full
HONG KONG, Feb. 9, 2021 /PRNewswire/ -- HH&L Acquisition Co. (NYSE: HHLA.U) has successfully closed its initial public offering of 41,400,000 units at $10.00 each, raising a total of $414 million. This includes 5,400,000 units from the exercise of the underwriters' over-allotment option. Each unit comprises one Class A ordinary share and one-half of a redeemable warrant, with full warrants priced at $11.50 per share. The securities began trading on February 5, 2021, and the company aims to target healthcare sectors primarily in Greater China.
- Raised $414 million through IPO, indicating strong investor interest.
- Focus on healthcare sectors in Greater China could lead to significant growth opportunities.
- Successful execution of over-allotment option shows confidence from underwriters.
- None.
HONG KONG, Feb. 9, 2021 /PRNewswire/ -- HH&L Acquisition Co. (NYSE: HHLA.U) (the "Company") today announced the closing of its initial public offering of 41,400,000 units, which includes 5,400,000 units issued pursuant to the exercise by the underwriters of their over-allotment option, at a public offering price of
The units are listed on the New York Stock Exchange ("NYSE") and commenced trading under the ticker symbol "HHLA.U" on February 5, 2021. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols "HHLA" and "HHLA WS," respectively.
HH&L Acquisition Co. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Although the Company's efforts to identify a prospective business combination opportunity will not be limited to a particular industry, it intends to focus on healthcare or healthcare-related companies in Asian markets with a focus on the Greater China market, or global healthcare or healthcare-related companies with a meaningful growth thesis in the Greater China or Asian markets, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value.
Goldman Sachs (Asia) L.L.C. and Credit Suisse Securities (USA) LLC acted as the representatives of the underwriters.
A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on February 4, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering was made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained from Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282, Attention: Prospectus Department, Telephone: 1-866-471-2526, Email: prospectus-ny@gs.com and Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, North Carolina 27560, Telephone: 1-800-221-1037, Email: usa.prospectus@credit-suisse.com.
Cautionary Note Concerning Forward-Looking Statements
This press release contains statements that constitute "forward-looking statements," including with respect to the Company's search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement for the initial public offering filed with the SEC. Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
View original content:http://www.prnewswire.com/news-releases/hhl-acquisition-co-announces-closing-of-upsized-414-million-initial-public-offering-and-exercise-of-underwriters-over-allotment-option-in-full-301225164.html
SOURCE HH&L ACQUISITION CO
FAQ
What is HH&L Acquisition Co.'s IPO amount?
When did HH&L Acquisition Co. start trading on the NYSE?
What is the ticker symbol for HH&L Acquisition Co.?
What kind of companies does HH&L Acquisition Co. intend to target?
What does each unit in HH&L Acquisition Co.'s IPO consist of?
